Search
Heron Therapeutics Inc
HRTXAdd to Watchlist
0.291USD
0.0000.00%
Close 09-23 16:00（ET）
55.08MMarket Cap
LossP/E TTM
Heron Therapeutics Inc (HRTX) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to Heron Therapeutics Inc in the past month.
Hold
0 Strong Buy
0 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
2.500USD+409.37%
HRTX Analyst Recommendation Trends
In the current month, HRTX has received 0 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. HRTX average Analyst price target in the last month is 2.500.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
1
0
0
1
3
3
3
3
3
2
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
3
3
3
3
4
HRTX Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, HRTX EPS is projected to reach -0.027 in FY2026Q3, following reported EPS of -0.029 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.02
-0.01
0.01
-0.03
-0.03
Actual
-0.12
-0.04
-0.03
--
--
Surprise
-505.70%
-185.13%
-388.40%
--
--
FAQs
What is Heron Therapeutics Inc's expected revenue for the next quarter?
Heron Therapeutics Inc's expected revenue is 37.50M.
What is Heron Therapeutics Inc's price target?
Analysts forecast that Heron Therapeutics Inc's price target is USD 2.50, with the highest forecast at USD 3.00 and the lowest forecast at USD 2.00.
How have Heron Therapeutics IncHRTX's recent earnings per share performed?
The market expectation was USD -0.03, while Heron Therapeutics IncHRTX's earnings per share (EPS) for the previous quarter was USD -0.04. EPS for the next quarter is expected at USD -0.03.
What is the analyst rating for Heron Therapeutics Inc?
Based on the ratings of Heron Therapeutics Inc's stock from 2 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.